Laboratorios Farmacéuticos Rovi, the Spanish headquartered pharmaceutical manufacturer, CDMO and R&D company, has decided to retain its CDMO business after evaluating several non-binding offers and deciding that continuing with its current strategic plan will maximize value for its existing shareholders.

Rovi had previously explored the potential of a sale of its CDMO segment - which includes manufacturing COVID-19 vaccines for Moderna – but rejected all five offers from potential buyers.

The following article originally appeared in Microsoft Start.

Laboratorios Farmaceuticos Rovi has released an update.

Laboratorios Farmacéuticos Rovi has decided to continue with its independent strategic plan for its CDMO business, rejecting external investment offers, due to its current strong performance and future prospects. The company aims to capitalize on its leadership in sterile fill and finish capacity, with expectations to expand its facilities in Spain, aligning with regulatory standards and market demand. This move is seen as a way to maximize shareholder value and foster further growth opportunities within its existing structure.

For more, please find the original story source here.